Ivarmacitinib for polymyalgia rheumatica
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy clinical trials.
This trial tests a new daily pill, ivarmacitinib, for people with polymyalgia rheumatica (PMR). It may help control symptoms without needing steroids long-term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 75 years old and weigh between 40 and 80 kg (about 88 to 176 lbs).
- You have been diagnosed with polymyalgia rheumatica (PMR) and your disease activity score is at least 17.
- If you are newly diagnosed, you have not taken steroids for PMR in the last 12 weeks. If you have relapsed, you have been on a stable steroid dose for at least 2 weeks and are willing to stop steroids.
- You do not have giant cell arteritis, lupus, other inflammatory diseases, or active fibromyalgia.
- You do not have uncontrolled diabetes, uncontrolled high blood pressure, significant heart rhythm problems, or a history of cancer (within 5 years) or blood clots.
- You do not have an active infection (like tuberculosis, hepatitis B/C, HIV, or serious shingles) and have not taken JAK inhibitors before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a once-daily pill called Ivarmacitinib (a JAK inhibitor) taken alone to see if it can improve symptoms in people with rheumatoid arthritis who have not responded well to standard treatments like methotrexate. The study aims to find a more effective option for those who need better control of their RA.
This study tests a new medication called ivarmacitinib for people with moderate-to-severe atopic dermatitis (severe itchy, inflamed skin) who haven't seen enough improvement from other similar treatments. Researchers want to see if switching to this new drug helps control symptoms better.
This trial tests a drug called Ivarmacitinib for people whose solid tumors stopped responding to immunotherapy due to side effects. It aims to see if Ivarmacitinib can help control the tumor while managing those side effects.
This trial tests if adding baricitinib (a pill that calms inflammation) to standard steroids works better than steroids alone for people with polymyalgia rheumatica. It aims to improve symptoms and reduce steroid side effects.
This trial tests a new oral medication (Ivarmacitinib) for people aged 12–75 with moderate-to-severe atopic dermatitis (a chronic skin condition causing red, itchy skin). The goal is to see if it improves symptoms safely in both adolescents and adults.
This study tests whether a daily pill (tofacitinib) combined with a short course of steroids can help people with active PMR use less steroids over time. You must have high disease activity and not have taken steroids or biologics in the past two weeks.
Hear when a new Polymyalgia Rheumatics (PMR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.